Progress in the management of patients with uveal melanoma. the 2012 Ashton Lecture

Eye (Basingstoke)

Volumn 26, Issue 9, 2012, Pages 1157-1172

  Damato, B ^a  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Detection; Diagnosis; Metastatic disease; Screening; Treatment; Uveal melanoma

Indexed keywords

ARTICLE; AUTOFLUORESCENCE; BIOMICROSCOPY; BRACHYTHERAPY; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CHROMOSOME 3; CHROMOSOME LOSS; COUNSELING; ENUCLEATION; GENE EXPRESSION PROFILING; HUMAN; LIVER PERFUSION; LIVER RESECTION; LIVER SCINTISCANNING; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT REFERRAL; PHOTODYNAMIC THERAPY; PHOTOTHERAPY; PROGNOSIS; PROTON THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SLIT LAMP; TREATMENT PLANNING; UVEA MELANOMA; VISION;

EID: 84867552282     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2012.126     Document Type: Article

References (76)

1. Damato BE, Coupland SE. Differences in uveal melanomas between men and women from the British Isles. Eye 2012; 26: 292-299.
2. Damato EM, Damato BE. Detection and time to treatment of uveal melanoma in the United Kingdom: An evaluation of 2384 patients. Ophthalmology 2012; e-pub ahead of print 11 April 2012; doi:10.1016/j.ophtha.2012.01.048.
3. Damato BE, Foulds WS. Tumour-associated retinal pigment epitheliopathy. Eye 1990; 4: 382-387.
4. Coupland SE, Campbell I, Damato B. Routes of extraocular extension of uveal melanoma: Risk factors and influence on survival probability. Ophthalmology 2008; 115: 1778-1785.
5. Eskelin S, Pyrhönen S, Hahka-Kemppinen M, Tuomaala S, Kivelä T. A prognostic model and staging for metastatic uveal melanoma. Cancer 2003; 97: 465-475.
6. Anderson MF, Callejo S, Bridson JD, Damato BE. Diagnostic information provided by referrers to patients with suspected uveal melanoma. Eye 2011; 25: 392.
7. Bridson JD, Damato B. Consent to rapid treatment of eye tumours: Is the waiting time too short at Liverpool Ocular Oncology Centre? Clin Ethics 2010; 5(2): 86-94.
8. Feinstein EG, Marr BP, Winston CB, Abramson DH. Hepatic abnormalities identified on abdominal computed tomography at diagnosis of uveal melanoma. Arch Ophthalmol 2010; 128: 319-323.
9. Ah-Fat FG, Sharma MC, Damato BE. Taping outpatient consultations: A survey of attitudes and responses of adult patients with ocular malignancy. Eye 1998; 12: 789-791.
10. Damato B. Does ocular treatment of uveal melanoma influence survival? Br J Cancer 2010; 103: 285-290.
11. Knapp H. A treatise on intraocular tumors, from original clinical observations and anatomical investigations. English translation; (edn) William Wood & Co.: New York, 1869.
12. Manschot WA, van Strik R. Is irradiation a justifiable treatment of choroidal melanoma? Analysis of published results. Br J Ophthalmol 1987; 71: 348-352.
13. Zimmerman LE, McLean IW, Foster WD. Does enucleation of the eye containing a malignant melanoma prevent or accelerate the dissemination of tumour cells. Br JOphthalmol 1978; 62: 420-425.
14. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report no. 28. Arch Ophthalmol 2006; 124: 1684-1693.
15. Hawkins BS. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24. Am J Ophthalmol 2004; 138: 936-951.
16. Damato B. Legacy of the collaborative ocular melanoma study. Arch Ophthalmol 2007; 125: 966-968.
17. Eskelin S, Pyrhönen S, Summanen P, Hahka-Kemppinen M, Kivelä T. Tumor doubling times in metastatic malignant melanoma of the uvea: Tumor progression before and after treatment. Ophthalmology 2000; 107: 1443-1449.
18. Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jöckel KH, Becher R. Prognostic implications of monosomy 3 in uveal melanoma. Lancet 1996; 347: 1222-1225.
19. Höglund M, Gisselsson D, Hansen GB, White VA, Säll T, Mitelman F et al. Dissecting karyotypic patterns in malignant melanomas: Temporal clustering of losses and gains in melanoma karyotypic evolution. Int J Cancer 2004; 108: 57-65.
20. Tschentscher F, Husing J, Holter T, Kruse E, Dresen IG, Jöckel KH et al. Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res 2003; 63: 2578-2584.
21. Damato B, Dopierala JA, Coupland SE. Genotypic profiling of 452 choroidal melanomas with multiplex ligationdependent probe amplification. Clin Cancer Res 2010; 16: 6083-6092.
22. Callejo SA, Dopierala J, Coupland SE, Damato B. Sudden growth of a choroidal melanoma and multiplex ligationdependent probe amplification findings suggesting late transformation to monosomy 3 type. Arch Ophthalmol 2011; 129: 958-960.
23. Meyer Schwickerath G, Vogel M. Treatment of malignant melanomas of the choroid by photocoagulation. Trans Ophthalmol Soc UK 1977; 97: 416-420.
24. Foulds WS, Damato BE. Low-energy long-exposure laser therapy in the management of choroidal melanoma. Graefes Arch Clin Exp Ophthalmol 1986; 224: 26-31.
25. Oosterhuis JA, Journee-de Korver HG, Kakebeeke-Kemme HM, Bleeker JC. Transpupillary thermotherapy in choroidal melanomas. Arch Ophthalmol 1995; 113: 315-321.
26. Lang GE, Mennel S, Spital G, Wachtlin J, Jurklies B, Heimann H et al. Different indications of photodynamic therapy in ophthalmology. Klin Monatsbl Augenheilkd 2009; 226: 725-739.
27. Moore RF. Choroidal sarcoma treated by the intraocular insertion of radon seeds. Br J Ophthalmol 1930; 14: 145-152.
28. Russo A, Laguardia M, Damato B. Eccentric ruthenium plaque radiotherapy of posterior choroidal melanoma. Graefes Arch Clin Exp Ophthalmol 2012; e-pub ahead of print 28 March 2012; PMID 22460679.
29. Damato B, Patel I, Campbell IR, Mayles HM, Errington RD. Visual acuity after Ruthenium(106) brachytherapy of choroidal melanomas. Int J Radiat Oncol Biol Phys 2005; 63: 392-400.
30. Damato B, Patel I, Campbell IR, Mayles HM, Errington RD. Local tumor control after (106)Ru brachytherapy of choroidal melanoma. Int J Radiat Oncol Biol Phys 2005; 63: 385-391.
31. Damato B, Kacperek A, Chopra M, Campbell IR, Errington RD. Proton beam radiotherapy of choroidal melanoma: The Liverpool-Clatterbridge experience. Int J Radiat Oncol Biol Phys 2005; 62: 1405-1411.
32. Daftari IK, Char DH, Verhey LJ, Castro JR, Petti PL, Meecham WJ. Anterior segment sparing to reduce charged particle radiotherapy complications in uveal melanoma. Int J Radiat Oncol Biol Phys 1997; 39: 997-1010.
33. Damato B, Kacperek A, Chopra M, Sheen MA, Campbell IR, Errington RD. Proton beam radiotherapy of iris melanoma. Int J Radiat Oncol Biol Phys 2005; 63: 109-115.
34. Tan AN, Hoevenaars JG, Webers CA, Damato B, Beckers HJ Baerveldt implant for secondary glaucoma due to iris melanoma, Clin Ophthalmol 2010; 4 407-409.
35. Tan AN, Hoevenaars JG,Webers CA, Damato B, Beckers HJ. Baerveldt implant for secondary glaucoma due to iris melanoma. Clin Ophthalmol 2010; 4: 407-409. 35 Damato EM, Damato B, Sibbring JS, Coupland SE. Ciliary body melanoma with partial deletion of chromosome 3 detected with multiplex ligation-dependent probe amplification. Graefes Arch Clin Exp Ophthalmol 2008; 246: 1637-1640.
36. Foulds WS. The local excision of choroidal melanomata. Trans Ophthalmol Soc UK 1973; 93: 343-346.
37. Damato BE, Paul J, Foulds WS. Risk factors for residual and recurrent uveal melanoma after trans-scleral local resection. Br J Ophthalmol 1996; 80: 102-108.
38. Damato BE, Paul J, Foulds WS. Risk factors for metastatic uveal melanoma after trans-scleral local resection. Br J Ophthalmol 1996; 80: 109-116.
39. Damato BE, Paul J, Foulds WS. Predictive factors of visual outcome after local resection of choroidal melanoma. Br J Ophthalmol 1993; 77: 616-623.
40. Damato B, Groenewald CP, McGalliard JN, Wong D. Rhegmatogenous retinal detachment after transscleral local resection of choroidal melanoma. Ophthalmology 2002; 109: 2137-2143.
41. Damato B, Groenewald C, McGalliard J, Wong D. Endoresection of choroidal melanoma. Br J Ophthalmol 1998; 82: 213-218.
42. Hadden PW, Hiscott PS, Damato BE. Histopathology of eyes enucleated after endoresection of choroidal melanoma. Ophthalmology 2004; 111: 154-160.
43. Damato B, Wong D, Green FD, Mackenzie JM. Intrascleral recurrence of uveal melanoma after transretinal "endoresection". Br J Ophthalmol 2001; 85: 114-115.
44. Bechrakis NE, Foerster MH. Neoadjuvant proton beam radiotherapy combined with subsequent endoresection of choroidal melanomas. Int Ophthalmol Clin 2006; 46: 95-107.
45. Schilling H, Bornfeld N, Talies S, Anastassiou G, Schü ler A, Horstmann GA. [Endoresection of large uveal melanomas after pretreatment by single-dose stereotactic convergence irradiation with the leksell gamma knife-first experience on 46 cases]. Klin Monbl Augenheilkd 2006; 223: 513-520.
46. Damato B, Lecuona K. Conservation of eyes with choroidal melanoma by a multimodality approach to treatment: An audit of 1632 patients. Ophthalmology 2004; 111: 977-983.
47. Sandinha T, Hebbar G, Kenawy N, Hope-Stone L, Damato B. A nurse-led ocular oncology clinic in Liverpool: Results of a 6-month trial. Eye 2012; e-pub ahead of print 20 April 2012; doi:10.1038/eye.2012.62.
48. Damato B, Eleuteri A, Taktak AF, Coupland SE. Estimating prognosis for survival after treatment of choroidal melanoma. Prog Retin Eye Res 2011; 30: 285-295.
49. Damato B, Coupland SE. A reappraisal of the significance of largest basal diameter of posterior uveal melanoma. Eye 2009; 23: 2152-2160.
50. Shields CL, Furuta M, Thangappan A, Nagori S, Mashayekhi A, Lally DR et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol 2009; 127: 989-998.
51. Finger PT. The 7th edition AJCC staging system for eye cancer: An international language for ophthalmic oncology. Arch Pathol Lab Med 2009; 133: 1197-1198.
52. Jmor F, Kalirai H, Taktak A, Damato B, Coupland SE. HSP-27 protein expression in uveal melanoma: Correlation with predicted survival. Acta Ophthalmol 2010; 10-3768.
53. Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010; 330: 1410-1413.
54. Angi M, Damato B, Kalirai H, Dodson A, Taktak A, Coupland SE. Immunohistochemical assessment of mitotic count in uveal melanoma. Acta Ophthalmol 2011; 89: E155-e160.
55. Damato B, Duke C, Coupland SE, Hiscott P, Smith PA, Campbell I et al. Cytogenetics of uveal melanoma: A 7-year clinical experience. Ophthalmology 2007; 114: 1925-1931.
56. Lake SL, Kalirai H, Dopierala J, Damato BE, Coupland SE. Comparison of formalin-fixed and snap-frozen samples analyzed by multiplex ligation-dependent probe amplification for prognostic testing in uveal melanoma. Invest Ophthalmol Vis Sci 2012; 53: 2647-2652.
57. Damato B, Dopierala J, Klaasen A, van Dijk M, Sibbring J, Coupland SE. Multiplex ligation-dependent probe amplification of uveal melanoma: Correlation with metastatic death. Invest Ophthalmol Vis Sci 2009; 50: 3048-3055.
58. Dopierala J, Damato BE, Lake SL, Taktak AF, Coupland SE. Genetic heterogeneity in uveal melanoma assessed by multiplex ligation-dependent probe amplification. Invest Ophthalmol Vis Sci 2010; 51: 4898-4905.
59. Scholes AG, Damato BE, Nunn J, Hiscott P, Grierson I, Field JK. Monosomy 3 in uveal melanoma: Correlation with clinical and histologic predictors of survival. Invest Ophthalmol Vis Sci 2003; 44: 1008-1011.
60. Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 2004; 64: 7205-7209.
61. Onken MD, Worley LA, Tuscan MD, Harbour JW. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn 2010; 12: 461-468.
62. Eleuteri A, Damato B, Coupland SE, Taktak AF. Enhancing survival prognostication in patients with choroidal melanoma by integrating pathologic, clinical and genetic predictors of metastasis. Int J Biomed EngTechnol 2012; 8: 18-35.
63. Hakulinen T, Teppo L, Saxen E. Cancer of the eye, a review of trends and differentials. World Health Stat Q 1978; 31: 143-158.
64. Cook SA, Damato B, Marshall E, Salmon P. Psychological aspects of cytogenetic testing of uveal melanoma: Preliminary findings and directions for future research. Eye 2009; 23: 581-585.
65. Kim IK, Lane AM, Gragoudas ES. Survival in patients with presymptomatic diagnosis of metastatic uveal melanoma. Arch Ophthalmol 2010; 128: 871-875.
66. Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD. Screening for metastasis from choroidal melanoma: The Collaborative Ocular Melanoma Study Group Report 23. J Clin Oncol 2004; 22: 2438-2444.
67. Servois V, Mariani P, Malhaire C, Petras S, Piperno-Neumann S, Plancher C et al. Preoperative staging of liver metastases from uveal melanoma by magnetic resonance imaging (MRI) and fluorodeoxyglucose-positron emission tomography (FDG-PET). Eur J Surg Oncol 2010; 36: 189-194.
68. Orcurto V, Denys A, Voelter Vet al. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: Results from a pilot study. Melanoma Res 2012; 22: 63-69.
69. Strobel K, Bode B, Dummer R, Schalenbourg A, Schnyder P, Zografos L. Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma. Eur J Nucl Med Mol Imaging 2009; 36: 1774-1782.
70. Maeda T, Tateishi U, Suzuki S, Arai Y, Kim EE, Sugimura K. Magnetic resonance screening trial for hepatic metastasis in patients with locally controlled choroidal melanoma. Jpn J Clin Oncol 2007; 37: 282-286.
71. Augsburger JJ, Correa ZM, Shaikh AH. Effectiveness of treatments for metastatic uveal melanoma. Am J Ophthalmol 2009; 148: 119-127.
72. Sato T. Locoregional management of hepatic metastasis from primary uveal melanoma. Semin Oncol 2010; 37: 127-138.
73. Alexander HR Jr., Libutti SK, Pingpank JF, Steinberg SM, Bartlett DL, Helsabeck C. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res 2003; 9: 6343-6349.
74. Mariani P, Piperno-Neumann S, Servois V, Berry MG, Dorval T. Surgical management of liver metastases from uveal melanoma: 16 years' experience at the Institut Curie. Eur J Surg Oncol 2009; 35: 1192-1197.
75. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
76. Klingenstein A, Haug AR, Zech CJ, Schaller UC. Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients. Cardiovasc Intervent Radiol 2012; e-pub ahead of print 21 April 2011; PMID: 22526099.